SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 8,500 Shares of Stock

Key Points

• Chairman Jurgi Camblong sold 8,500 SOPHiA GENETICS shares at an average price of $7.26, generating $61,710. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 3.39 million shares.
• SOPHiA GENETICS shares fell 0.4% to $7.06, while the company continues to report losses. Its latest quarterly EPS of negative $0.26 missed estimates, although revenue of $23.31 million exceeded expectations.
• Analyst sentiment is mixed, with an average rating of Hold and an average price target of $10.00; institutional investors own approximately 31.6% of the company.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 8,500 shares of the business's stock in a transaction on Monday, October 12th. The shares were sold at an average price of $7.26, for a total transaction of $61,710.00. Following the sale, the chairman owned 3,387,150 shares in the company, valued at approximately $24,590,709. This trade represents a 0.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, October 5th, Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.13, for a total transaction of $326,598.36.
• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total transaction of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total value of $153,356.49.

SOPHiA GENETICS Stock Down 0.4%

Shares of SOPHiA GENETICS stock traded down $0.03 during midday trading on Wednesday, hitting $7.06. The company had a trading volume of 376,763 shares, compared to its average volume of 310,258. SOPHiA GENETICS SA has a 52-week low of $3.75 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The stock has a market capitalization of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The company has a 50 day moving average of $7.95 and a 200 day moving average of $6.20.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter worth $9,809,000. Principal Financial Group Inc. lifted its stake in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after buying an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Sei Investments Co. bought a new position in SOPHiA GENETICS in the 1st quarter worth $1,772,000. Finally, 1492 Capital Management LLC boosted its holdings in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock worth $1,117,000 after buying an additional 17,406 shares during the period. 31.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SOPH has been the topic of several research reports. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research note on Monday. Zacks Research raised SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.